In this new role as CMO, Dr Williams will be responsible for patient safety, general medical governance, ethics and integrity, medical information and investigations involving human subjects relating to Neotropix’s anticancer products in clinical development.
Dr Williams joins Neotropix from Synta Pharmaceuticals, where he was vice president of medical research and part of the GlaxoSmithKline-Synta development team.
Peter Lanciano, CEO of Neotropix, said: “We are excited to have Tony as a member of the team. His depth of medical expertise, general management and business development experience in both large and small pharmaceutical and biotechnology companies, as well as his proven leadership skills make him ideally suited for this critical role within Neotropix.”